VEGFA和VEGFR2对肺腺癌患者术后无病生存的预测价值
发布时间：2018-10-10 18:47
【摘要】：目的 :探讨血管内皮生长因子A(vascular endothelial growth factor A,VEGFA)和血管内皮生长因子受体2(vascular endothelial growth factor receptor 2,VEGFR2)与肺腺癌患者术后无病生存(disease-free survival,DFS)之间的相关性。方法:选择114例肺腺癌术后肿瘤组织标本,应用免疫组织化学法(immunohistochemistry,IHC)检测VEGFA及VEGFR2蛋白的表达情况。收集肺腺癌患者的性别、年龄、吸烟情况、肿瘤大小、阳性淋巴结(positive lymph nod,PLN)数目、临床分期和术后治疗情况等临床资料,分析VEGFA和VEGFR2与这些临床特征的相关性。COX比例风险回归模型分析影响肺腺癌患者术后DFS的相关因素。结果:IHC检测结果显示,VEGFA和VEGFR2在NSCLC患者肺腺癌组织中的阳性表达率均为46.49%(53/114)。VEGFA蛋白的表达与患者的临床特征无显著相关性,而VEGFR2蛋白的表达与肿瘤大小存在负相关(P=0.03)。单因素分析显示,VEGFA与VEGFR2蛋白的表达与患者DFS无显著相关性。肿瘤大小4 cm(相对风险为2.29,95%可信区间为1.32~3.97;P=0.003)和PLN数≥2个(相对风险为2.15,95%可信区间为1.27~3.64;P=0.005)是肺腺癌患者术后DFS的独立危险因素。结论:VEGFA和VEGFR2蛋白的表达与肺腺癌患者术后DFS无显著相关性。肿瘤大小4 cm和PLN数≥2个是肺腺癌患者术后DFS的独立影响因素。
[Abstract]:Objective: to investigate the relationship between vascular endothelial growth factor (A (vascular endothelial growth factor) and vascular endothelial growth factor receptor 2 (vascular endothelial growth factor receptor 2 VEGF R2 and disease-free survival (disease-free survival,DFS) in patients with lung adenocarcinoma. Methods: immunohistochemical method (immunohistochemistry,IHC) was used to detect the expression of VEGFA and VEGFR2 protein in 114 cases of lung adenocarcinoma after operation. The data of sex, age, smoking status, tumor size, number of positive lymph nodes (positive lymph nod,PLN), clinical stage and postoperative treatment of lung adenocarcinoma patients were collected. The correlation between VEGFA and VEGFR2 and these clinical features was analyzed. COX proportional risk regression model was used to analyze the related factors of postoperative DFS in patients with lung adenocarcinoma. Results: IHC showed that the positive expression rate of VEGFA and VEGFR2 was 46.49% (53 / 114). VEGFA protein was not correlated with the clinical features of the patients with NSCLC), while the expression of VEGFR2 protein was negatively correlated with the tumor size (P0. 03). Univariate analysis showed that there was no significant correlation between the expression of VEGFA and VEGFR2 protein and DFS. Tumor size 4 cm (relative risk 2.29 95% CI = 1.32) and PLN number 鈮，
本文编号：2262856
[Abstract]:Objective: to investigate the relationship between vascular endothelial growth factor (A (vascular endothelial growth factor) and vascular endothelial growth factor receptor 2 (vascular endothelial growth factor receptor 2 VEGF R2 and disease-free survival (disease-free survival,DFS) in patients with lung adenocarcinoma. Methods: immunohistochemical method (immunohistochemistry,IHC) was used to detect the expression of VEGFA and VEGFR2 protein in 114 cases of lung adenocarcinoma after operation. The data of sex, age, smoking status, tumor size, number of positive lymph nodes (positive lymph nod,PLN), clinical stage and postoperative treatment of lung adenocarcinoma patients were collected. The correlation between VEGFA and VEGFR2 and these clinical features was analyzed. COX proportional risk regression model was used to analyze the related factors of postoperative DFS in patients with lung adenocarcinoma. Results: IHC showed that the positive expression rate of VEGFA and VEGFR2 was 46.49% (53 / 114). VEGFA protein was not correlated with the clinical features of the patients with NSCLC), while the expression of VEGFR2 protein was negatively correlated with the tumor size (P0. 03). Univariate analysis showed that there was no significant correlation between the expression of VEGFA and VEGFR2 protein and DFS. Tumor size 4 cm (relative risk 2.29 95% CI = 1.32) and PLN number 鈮，
本文编号：2262856
本文链接：https://www.wllwen.com/yixuelunwen/zlx/2262856.html
